Navigation Links
Breakthrough in combating the side effects of quinine
Date:6/29/2009

Discovered back in the 1600s quinine was the first effective treatment in the fight against malaria and it continues to be a commonly used treatment against this devastating disease. But the drug is associated with a long list of side effects which can range from sickness and headaches to blindness, deafness and in rare cases death and until now no one knew why.

Scientists at The University of Nottingham have made a discovery that may explain many of the adverse side-effects associated with the drug and as a result have potentially found a way of combating them.

Their research, funded by The Sir Halley Stewart Trust, found that quinine can block a cell's ability to take up the essential amino acid tryptophan. The findings, published today in the Journal of Biological Chemistry, suggest that dietary tryptophan supplements could be a cheap and simple way to improve the performance of this important drug.

Dr Simon Avery and colleagues in the School of Biology used yeast genetics to examine the effects of quinine on a collection of 6000 yeast mutants, each one lacking exactly one of the yeast's 6000 genes. While quite different from humans, yeast is comparable on a cellular level and yeast is frequently, and successfully, used as a front-line agent in testing chemicals and small molecule drugs.

This detailed screening process revealed that strains of yeast unable to make tryptophan were extremely susceptible to quinine poisoning, which led them to identify a tryptophan transporter as a key quinine target (yeast that cannot make their own tryptophan have to rely exclusively on external sources, and thus die if tryptophan transport is blocked).

This discovery fits in well with evidence that quinine reactions are more severe in malnourished individuals. Tryptophan is an essential amino acid which means the human body cannot produce it we have to get it from the food we eat. Tryptophan is abundant in meat but limit
'/>"/>

Contact: Dr. Simon Avery
simon.avery@nottingham.ac.uk
44-011-595-13315
University of Nottingham
Source:Eurekalert

Page: 1 2

Related medicine news :

1. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
2. drugstore.com and Revolution Health Group Announce Breakthrough Deal
3. New Round of Lupus Research Institute Awards Brings Promise of More Breakthroughs
4. CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency
5. Oosight Imaging System Enables a Breakthrough: The Viable Transfer of Genetic Material for Stem Cell Nuclear Reprogramming in Primates
6. Breakthrough in organ rejection diagnosis examines gene behavior
7. Safe Sex Passport Launches to Provide Breakthrough Protection Against STDs and HIV
8. Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome
9. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
10. TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007
11. California Breakthrough a Pivotal Moment in Fight to Transform Nations Health Care System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
(Date:7/13/2014)... 13, 2014 Fadhits.com is popular among ... dresses are extremely beautiful. Recently, the company has announced ... for 2014. What’s more, all these outfits are available ... , Additionally, the supplier is now offering similar ... Quinceanera dresses, it has many other designs for sale, ...
(Date:7/13/2014)... A decreased ability to identify odors might ... disease, while examinations of the eye could indicate ... Alzheimer,s, in the brain, according to the results ... Alzheimer,s Association International Conference 2014 (AAIC 2014) in ... decreased ability to identify odors was significantly associated ...
(Date:7/13/2014)... 13, 2014 A Xarelto lawsuit ... LLC to provide consumers with the most current information ... of the blood-thinning medication, as well as the ... courts around the country. The law firm is now ... suffered from life-threatening internal bleeding and related complications while ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today ... at the Tamarack Senior Living Community in Palatine, IL. The ... on the 3rd Wednesdays of every month. This group ... Community located at 55 S. Greeley St. Palatine, IL 60067. ... is no cost for the group. , “A grief ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... Systems (TSX: LMZ,AMEX: LMZ), a healthcare technology company ... for obstetrics, today announced that its,Board of Directors ... from Amex., The decision is in keeping ... control costs in order to become cash flow,positive. ...
... Presentations highlight Palomid 529 as an inhibitor of macular ... ... JAMAICA PLAIN, Mass., May 1 Paloma Pharmaceuticals,Inc. today announced ... the Association for Research in Vision and Ophthalmology (ARVO),describing the ...
... The Cosmetic Bootcamp LLC,announced today that its summer ... According to Dr. Kenneth Beer, this year,s meeting is,expected ... meeting has,experienced since its inception four years ago. Dr. ... credibility the meeting has gained with both,physicians and industry. ...
... 1 Perrigo Company,(Nasdaq: PRGO ; TASE) ... a,quarterly dividend of $0.05 per share, payable on ... 25, 2008., Perrigo Company is a leading ... (OTC) and prescription,pharmaceuticals, nutritional products, active pharmaceutical ingredients,(API) ...
... MedCath Corporation,(Nasdaq: MDTH ) announced that its ... Securities 33rd Annual Health Care,Conference held May 5 - ... management will give its presentation on Wednesday,May 7 at ... live over the,Internet via MedCath,s website ( http://www.medcath.com ) ...
... increases 5 percent to $22.9 billion, - GAAP earnings from continuing operations reach $366 million from ... of $5 million in the prior-year period, - GAAP diluted earnings per share from ... from a loss of $0.01 in prior-year period, - Non-GAAP diluted EPS from ... ...
Cached Medicine News:Health News:LMS to delist from Amex 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 2Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 3Health News:Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting 4Health News:Cardinal Health Reports Third Quarter Results 2Health News:Cardinal Health Reports Third Quarter Results 3Health News:Cardinal Health Reports Third Quarter Results 4Health News:Cardinal Health Reports Third Quarter Results 5Health News:Cardinal Health Reports Third Quarter Results 6Health News:Cardinal Health Reports Third Quarter Results 7Health News:Cardinal Health Reports Third Quarter Results 8Health News:Cardinal Health Reports Third Quarter Results 9Health News:Cardinal Health Reports Third Quarter Results 10Health News:Cardinal Health Reports Third Quarter Results 11Health News:Cardinal Health Reports Third Quarter Results 12Health News:Cardinal Health Reports Third Quarter Results 13Health News:Cardinal Health Reports Third Quarter Results 14Health News:Cardinal Health Reports Third Quarter Results 15Health News:Cardinal Health Reports Third Quarter Results 16Health News:Cardinal Health Reports Third Quarter Results 17Health News:Cardinal Health Reports Third Quarter Results 18Health News:Cardinal Health Reports Third Quarter Results 19Health News:Cardinal Health Reports Third Quarter Results 20Health News:Cardinal Health Reports Third Quarter Results 21Health News:Cardinal Health Reports Third Quarter Results 22Health News:Cardinal Health Reports Third Quarter Results 23Health News:Cardinal Health Reports Third Quarter Results 24Health News:Cardinal Health Reports Third Quarter Results 25Health News:Cardinal Health Reports Third Quarter Results 26Health News:Cardinal Health Reports Third Quarter Results 27Health News:Cardinal Health Reports Third Quarter Results 28Health News:Cardinal Health Reports Third Quarter Results 29Health News:Cardinal Health Reports Third Quarter Results 30Health News:Cardinal Health Reports Third Quarter Results 31
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... , , MOUNTAIN VIEW, Calif. ... announced the initiation of a Phase I clinical trial ... autoimmune diseases.  CCX168 is a highly potent and very ... a component of the body,s complement system and a ...
... , Jan. 28 , Net Sales of $1.11 ... period (an increase of 2.5% constant currency) , Diluted ... from the prior year period, and $1.12 adjusted, an increase of 12.0% ... of $4.10 billion for the full year represent a decrease of 0.6% ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 2ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 3ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 4Zimmer Reports Fourth Quarter and 2009 Financial Results 2Zimmer Reports Fourth Quarter and 2009 Financial Results 3Zimmer Reports Fourth Quarter and 2009 Financial Results 4Zimmer Reports Fourth Quarter and 2009 Financial Results 5Zimmer Reports Fourth Quarter and 2009 Financial Results 6Zimmer Reports Fourth Quarter and 2009 Financial Results 7Zimmer Reports Fourth Quarter and 2009 Financial Results 8Zimmer Reports Fourth Quarter and 2009 Financial Results 9Zimmer Reports Fourth Quarter and 2009 Financial Results 10Zimmer Reports Fourth Quarter and 2009 Financial Results 11Zimmer Reports Fourth Quarter and 2009 Financial Results 12Zimmer Reports Fourth Quarter and 2009 Financial Results 13Zimmer Reports Fourth Quarter and 2009 Financial Results 14Zimmer Reports Fourth Quarter and 2009 Financial Results 15Zimmer Reports Fourth Quarter and 2009 Financial Results 16Zimmer Reports Fourth Quarter and 2009 Financial Results 17Zimmer Reports Fourth Quarter and 2009 Financial Results 18Zimmer Reports Fourth Quarter and 2009 Financial Results 19Zimmer Reports Fourth Quarter and 2009 Financial Results 20Zimmer Reports Fourth Quarter and 2009 Financial Results 21Zimmer Reports Fourth Quarter and 2009 Financial Results 22Zimmer Reports Fourth Quarter and 2009 Financial Results 23Zimmer Reports Fourth Quarter and 2009 Financial Results 24Zimmer Reports Fourth Quarter and 2009 Financial Results 25Zimmer Reports Fourth Quarter and 2009 Financial Results 26Zimmer Reports Fourth Quarter and 2009 Financial Results 27
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: